ATE477799T1 - Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung - Google Patents

Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung

Info

Publication number
ATE477799T1
ATE477799T1 AT06709121T AT06709121T ATE477799T1 AT E477799 T1 ATE477799 T1 AT E477799T1 AT 06709121 T AT06709121 T AT 06709121T AT 06709121 T AT06709121 T AT 06709121T AT E477799 T1 ATE477799 T1 AT E477799T1
Authority
AT
Austria
Prior art keywords
production
compositions containing
containing same
substituted pyrazolopyridines
pyrazolopyridines
Prior art date
Application number
AT06709121T
Other languages
English (en)
Inventor
Baptiste Ronan
Michel Tabart
Frank Halley
Eric Bacque
Catherine Souaille
Antonio Ugolini
Fabrice Viviani
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE477799(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0500555A external-priority patent/FR2880891B1/fr
Priority claimed from FR0507505A external-priority patent/FR2888579A1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE477799T1 publication Critical patent/ATE477799T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06709121T 2005-01-19 2006-01-18 Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung ATE477799T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0500555A FR2880891B1 (fr) 2005-01-19 2005-01-19 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
FR0507505A FR2888579A1 (fr) 2005-07-13 2005-07-13 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PCT/FR2006/000114 WO2006077319A1 (fr) 2005-01-19 2006-01-18 Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
ATE477799T1 true ATE477799T1 (de) 2010-09-15

Family

ID=36593766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709121T ATE477799T1 (de) 2005-01-19 2006-01-18 Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung

Country Status (24)

Country Link
US (2) US8008322B2 (de)
EP (1) EP1845978B1 (de)
JP (1) JP2008527025A (de)
KR (1) KR20070098923A (de)
AR (1) AR052357A1 (de)
AT (1) ATE477799T1 (de)
AU (1) AU2006207442A1 (de)
BR (1) BRPI0606504A2 (de)
CA (1) CA2595041A1 (de)
CY (1) CY1110926T1 (de)
DE (1) DE602006016233D1 (de)
DK (1) DK1845978T3 (de)
HR (1) HRP20100624T8 (de)
IL (1) IL184524A0 (de)
MX (1) MX2007008790A (de)
PA (1) PA8660301A1 (de)
PE (1) PE20061119A1 (de)
PL (1) PL1845978T3 (de)
PT (1) PT1845978E (de)
RU (1) RU2375360C2 (de)
SI (1) SI1845978T1 (de)
TW (1) TW200639173A (de)
UY (1) UY29341A1 (de)
WO (1) WO2006077319A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (de) 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Arylpyrazolopyridine und ihre Salze, diese enthaltende pharmazeutische Zubereitungen, verfahren zu ihrer Herstellung und ihre Verwendung
EP1932845A1 (de) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-Pyrazolopyridine und Salze davon, diese enthaltende pharmazeutische Zusammensetzungen , Verfahren zur ihrer Herstellung und ihre Verwendung
KR20090088962A (ko) * 2006-12-15 2009-08-20 바이엘 쉐링 파마 악티엔게젤샤프트 ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도
EP2042500A1 (de) * 2007-09-21 2009-04-01 Bayer Schering Pharma Aktiengesellschaft N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-Harnstoff-Verbindungen deren pharmazeutische Zusammensetzungen, Verfahren zu deren Herstellung und Verwendungen als Tie2-Kinase Hemmer
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
EP2789615B1 (de) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazole als BTK-Kinasemodulatoren und Verwendung davon
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
WO2012064815A1 (en) 2010-11-12 2012-05-18 Bristol-Myers Squibb Company Substituted azaindazole compounds
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
BR112014003296A2 (pt) * 2011-08-12 2017-03-14 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
CA2864389A1 (en) 2012-02-20 2013-08-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105050598B (zh) * 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
CN104995184B (zh) 2012-12-28 2018-01-02 晶体基因技术株式会社 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
BR112020018383A2 (pt) 2018-04-05 2020-12-29 Merck Patent Gmbh Compostos heteroarílicos como inibidores da irak tipo ii e usos dos mesmos
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CA3241624A1 (en) * 2021-12-22 2023-06-29 Anaxis Pharma Pty Ltd Arylsulphonamide compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182896B (de) * 1963-04-02 1964-12-03 Merck Ag E Fungizide Mittel
ES2299434T3 (es) 1999-09-17 2008-06-01 ABBOTT GMBH & CO. KG Inhibidores de kinasa utilizados como agentes terapeuticos.
PL359416A1 (en) * 2000-07-18 2004-08-23 Yamanouchi Pharmaceutical Co, Ltd. Medicine comprising dicyanopyridine derivative
KR100904157B1 (ko) * 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
WO2004009596A2 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
BR0313396A (pt) * 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2005325099A (ja) * 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ES2386027T3 (es) * 2004-10-29 2012-08-07 Abbott Laboratories Inhibidores de quinasas novedosos
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
EP1683796A1 (de) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridine, ihre Herstellung und ihre medizinische Verwendung
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CN101316849A (zh) 2005-11-09 2008-12-03 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮及其制备和用途
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (de) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Arylpyrazolopyridine und ihre Salze, diese enthaltende pharmazeutische Zubereitungen, verfahren zu ihrer Herstellung und ihre Verwendung
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Also Published As

Publication number Publication date
WO2006077319A1 (fr) 2006-07-27
HRP20100624T8 (hr) 2011-01-31
KR20070098923A (ko) 2007-10-05
MX2007008790A (es) 2007-09-11
CY1110926T1 (el) 2015-06-10
US8008322B2 (en) 2011-08-30
US20110190337A1 (en) 2011-08-04
HRP20100624T1 (hr) 2010-12-31
PT1845978E (pt) 2010-11-29
IL184524A0 (en) 2007-10-31
RU2007131274A (ru) 2009-02-27
TW200639173A (en) 2006-11-16
PA8660301A1 (es) 2006-09-08
PL1845978T3 (pl) 2011-02-28
AR052357A1 (es) 2007-03-14
DK1845978T3 (da) 2010-12-13
US20080039491A1 (en) 2008-02-14
PE20061119A1 (es) 2006-11-27
BRPI0606504A2 (pt) 2009-06-30
SI1845978T1 (sl) 2010-12-31
JP2008527025A (ja) 2008-07-24
AU2006207442A1 (en) 2006-07-27
EP1845978A1 (de) 2007-10-24
DE602006016233D1 (de) 2010-09-30
UY29341A1 (es) 2006-08-31
EP1845978B1 (de) 2010-08-18
CA2595041A1 (fr) 2006-07-27
RU2375360C2 (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
ATE477799T1 (de) Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung
ATE433976T1 (de) Substituierte pyrrolopyridine, zusammensetzungen damit und verfahren zu ihrer herstellung und verwendung
EP1919703A4 (de) Verbundwerkstoffe mit modulierter zusammensetzung und verfahren zu deren herstellung
EP2084249A4 (de) Brennstoffzusammensetzungen mit farnesan und farnesanderivaten sowie verfahren zu ihrer herstellung und verwendung
DE602005007419D1 (de) Rohmix-pulverzusammensetzungen und verfahren zu deren herstellung
DE602006020386D1 (de) Duraimplantat und Verfahren zu seiner Herstellung
EP1800317A4 (de) Isolatorbeschichtung und verfahren zu ihrer herstellung
DE602006012666D1 (de) Ren eignen und verfahren zu deren herstellung
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
ATE556077T1 (de) Tetrahydrochinolinderivate und verfahren zu deren herstellung
EP2145887A4 (de) Substituierte 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole, verfahren für ihre herstellung und verwendung
EP1921674A4 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE602004015907D1 (de) Konjugierte Dienamide, Verfahren zur deren Herstellung, diese enthaltende Zusammensetzungen sowie deren Verwendung
ATE526307T1 (de) Hydroxybiphenyl-carbonsäuren und derivate, verfahren zu deren herstellung und deren verwendung
EP2350013A4 (de) Zusammensetzungen zur markierung und identifizierung von autophagosomen sowie verfahren zu ihrer herstellung und verwendung
DE602005023199D1 (de) Darreichungsformen mit mikroreliefoberfläche sowie verfahren und vorrichtung für deren herstellung
DE502006005961D1 (de) Endoskop und Verfahren zu seiner Herstellung
DE602006013001D1 (de) Zusammensetzung mit verbesserter stabilität und verfahren zu ihrer herstellung
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE602007005601D1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
DE602005018911D1 (de) 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
DE112005003550A5 (de) Flüssige Bio-Brennstoffmischung sowie Verfahren und Vorrichtung zur Herstellung derselben
DE502006009351D1 (de) Feinteiliges azopigment und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1845978

Country of ref document: EP